Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System
24.6.2021 20:17:00 EEST | Business Wire | Press release
Invivoscribe, a global leader in precision diagnostics, has announced the launch of an Immune Biomarker Discovery grant program, focused on supporting development, validation and deployment of novel applications for use of their distributed LymphoTrack® NGS products and bioinformatics software.
Massively parallel sequencing coupled with reagents targeting the immune receptor loci have accelerated our understanding of the immune response and immunology related disease processes. The availability of distributed RUO LymphoTrack tests and bioinformatics have eliminated a majority of the barriers of a service model approach, and have accelerated the ability to identify, track and monitor biomarkers associated with hematologic malignancies. These products are also being deployed worldwide to track the manufacture and treatment of immunotherapy, such as CAR T-cell therapies, and provide a comprehensive way to track a subject’s immune response to disease processes and to vaccines.
In conversations with customers and partners worldwide, we have also realized that our Research Use Only (RUO) LymphoTrack® sequencing kits and services also have utility far beyond clinical oncology, as these assays and software products are currently being used in research in areas as diverse as, studies of celiac disease and other autoimmune diseases, tracking the immune health of astronauts on the ISS, examining the immune response throughout the course of clinical treatments, and identifying changes in the immune repertoire with onset and progression of disease. Intrigued to learn what innovative applications our RUO LymphoTrack kits and services are being used for, we decided to launch this grant program to support these endeavors.
Successful innovative proposals submitted by applicants to our Invivoscribe’s Immune Biomarker Discovery grant program will receive LymphoTrack kits, controls and software to support their R&D project. Grants will be awarded to support cutting-edge research and development in academic, government and early-stage commercial laboratories conducting promising research studies.
“The combined costs of library preparation reagents, NGS sequencing reagents, and development of bioinformatics software represent an obstacle for researchers. The idea of this grant program is to reduce these financial barriers, thus empowering a few progressive laboratories to bring their groundbreaking applications to fruition,” says Tony Lialin, Chief Commercial Officer at Invivoscribe. Those selected as winners of the grant will not only receive NGS products, but will be provided additional opportunities to collaborate with Invivoscribe’s global network of ISO15189 accredited LabPMM laboratories. The laboratories selected for the grant program will also be featured in upcoming webinars and will be invited to speak at a number of symposiums around the world.
Details and How to Apply/Submit a Proposal
If your laboratory is interested in applying for Invivoscribe’s Immune Biomarker Discovery grant program to improve the standard of healthcare, we encourage you to submit research proposals that focus on the development of engineered antibodies to target antigens of infectious pathogens, toxins, allergens, and malignant diseases such as cancer and autoimmune disorders. More information about the program and details about how to submit a proposal can be found at www.invivoscribe.com/NGS-Grant. Proposals will be accepted from qualified laboratories across the world through Aug. 31, 2021 and winners will be announced by September 30, 2021. Additional information about the grant program and our oncology products and services can be requested by emailing sales@invivoscribe.com.
About Invivoscribe
Invivoscribe has been Improving Lives with Precision Diagnostics® for more than twenty-five years, advancing the field of precision medicine by developing and providing standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe has significantly impacted global health, working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM), Invivoscribe has demonstrated it is an ideal partner. For additional information please visit us at www.invivoscribe.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005113/en/
Contact information
Tony Lialin
inquiry@invivoscribe.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Completes Majority Acquisition in Italy-Based ISEM Packaging Group for AED 704 Million5.3.2026 23:02:00 EET | Press release
2PointZero Group PJSC (ADX: 2PointZero), a next-generation investment powerhouse focused on energy and consumer sectors, announced today that it has formally completed the transaction to acquire a majority position in ISEM, a leading European packaging group serving beauty, fashion, luxury, nutraceuticals and more, for AED 704 million through a combination of secondary and primary capital earmarked to accelerate organic and inorganic growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305800523/en/ 2PointZero Group completes majority acquisition in Italy-based ISEM Packaging Group for AED 704 million (Photo: AETOSWire) 2PointZero Group now holds 60.8% of ISEM, while Peninsula Capital and minority investors own the remaining 39.2%. This marks the start of a strategic partnership between 2PointZero and Peninsula. Together, the partners will reinforce ISEM’s leadership position with a focus on category and geographic expa
Xsolla Announces Reseller Program to Help Game Developers Unlock New Revenue Streams in Local Markets5.3.2026 19:00:00 EET | Press release
Xsolla, a leading global video game commerce company, today announced the Xsolla Reseller Program, a new product designed to help game developers scale and capture untapped revenue in local markets with no development needed. The program launches with a curated cohort of resellers and distributors in Southeast Asia and Latin America, with expansion into additional regions throughout 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305047070/en/ Graphic: Xsolla As game developers pursue global growth, they face a fundamental infrastructure challenge: billions of dollars in revenue remain untapped in emerging, cash-dependent economies, such as Southeast Asia, Latin America, the Middle East, and North Africa, where players purchase digital content through local distribution partners. In mature digital economies, developers seek to extend their reach and distribute digital inventory at scale through more partners and chan
Xsolla Agency Launches to Empower Creators Across Entertainment-Based Intellectual Property5.3.2026 17:23:00 EET | Press release
Xsolla, a global video game commerce company, today launched Xsolla Agency, a comprehensive service connecting game developers with premium entertainment-based intellectual property (IP). The integrated offering addresses critical challenges for game creators: access to world-class IP, global monetization capabilities, and the operational infrastructure needed to build sustainable businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305044119/en/ Graphic: Xsolla Xsolla Agency simplifies access to entertainment-based licenses through expert-led negotiations and industry relationships, offering affordable, monetization-focused deals structured for maximum ROI. Strategic IP partnerships increase discoverability, reduce user acquisition costs, and drive higher player spend through impactful LiveOps events and promotional campaigns. The service is backed by the same commerce infrastructure powering 1,500+ game developers
Onego Bio and Sigma Foods Enter Collaboration to Strengthen Egg Protein Innovation and Supply Resilience5.3.2026 17:00:00 EET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein, and Sigma Foods ("SIGMA"), a leading multinational food company, have entered into a collaboration agreement to evaluate the functionality and commercial potential of Bioalbumen®, a non-animal egg protein made with using precision fermentation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305756400/en/ The partnership focuses on advancing ingredient innovation while addressing urgent challenges in today’s egg supply chain—including volatility, rising prices, and avian flu-related disruptions. Bioalbumen® offers a shelf-stable, animal-free alternative that delivers the same functional, nutritional, and sensory performance as traditional eggs, while helping safeguard supply continuity for food manufacturers. Additionally, this collaboration supports Sigma’s commitment to offering safe, nutritious, and high-quality food, while driving science-based inno
Vertex to Present New Data on JOURNAVX ® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures5.3.2026 17:00:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14 days), demonstrating the potential for JOURNAVX as a core element of opioid-free multimodal treatment for moderate-to-severe acute pain after aesthetic and reconstructive procedures. In contrast, the literature shows opioid-free rates of less than 10% with multimodal treatment without JOURNAVX. These data will be presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting, March 5-8, 2026, in Salt Lake City, UT. This Phase 4 open-label, multicenter, single-arm study evaluated JOURNAVX w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom